Evidence map›Paper›PMID 34567246›Full record

ArticleEcancermedicalscience2021

Hereditary breast cancer and ancestry in the Madeira archipelago: an exploratory study.

Isália Miguel, Fátima Rodrigues, Sofia Fragoso, João Freixo, Ana Clara, Ana Luís, Sandra Bento, Mariana Fernandes, Filipe Bacelar, Sara Câmara and 5 more

Abstract read
In one paragraph

Article in Ecancermedicalscience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Frontiers in oncology · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Double Heterozygosity for Rare Deleterious Variants in theInternational journal of molecular sciences · 2023
    Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Isália MiguelInstituto Português de Oncologia de Lisboa Francisco Gentil, EPE, Rua Prof. Lima Basto 1099-023 Lisboa, Portugal.
Fátima RodriguesInstituto Português de Oncologia de Lisboa Francisco Gentil, EPE, Rua Prof. Lima Basto 1099-023 Lisboa, Portugal.
Sofia FragosoInstituto Português de Oncologia de Lisboa Francisco Gentil, EPE, Rua Prof. Lima Basto 1099-023 Lisboa, Portugal.
João FreixoCGPP-IBMC-i3S - Centro de Genética Preditiva e Preventiva, Instituto de Biologia Molecular e Celular, Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Rua Júlio Amaral de Carvalho 45, 4200-135 Porto, Portugal.
Ana ClaraInstituto Português de Oncologia de Lisboa Francisco Gentil, EPE, Rua Prof. Lima Basto 1099-023 Lisboa, Portugal.
Ana LuísInstituto Português de Oncologia de Lisboa Francisco Gentil, EPE, Rua Prof. Lima Basto 1099-023 Lisboa, Portugal.
Sandra BentoInstituto Português de Oncologia de Lisboa Francisco Gentil, EPE, Rua Prof. Lima Basto 1099-023 Lisboa, Portugal.
Mariana FernandesHospital Dr Nélio Mendonça, SESARAM, EPE, Avenida Luís de Camões 57, 9004-514 Funchal, Portugal.
Filipe BacelarHospital Dr Nélio Mendonça, SESARAM, EPE, Avenida Luís de Camões 57, 9004-514 Funchal, Portugal.
Sara CâmaraHospital Dr Nélio Mendonça, SESARAM, EPE, Avenida Luís de Camões 57, 9004-514 Funchal, Portugal.
Joana ParreiraInstituto Português de Oncologia de Lisboa Francisco Gentil, EPE, Rua Prof. Lima Basto 1099-023 Lisboa, Portugal.
Teresa DuarteInstituto Português de Oncologia de Lisboa Francisco Gentil, EPE, Rua Prof. Lima Basto 1099-023 Lisboa, Portugal.
Paula RodriguesInstituto Português de Oncologia de Lisboa Francisco Gentil, EPE, Rua Prof. Lima Basto 1099-023 Lisboa, Portugal.
Sidónia SantosInstituto Português de Oncologia de Lisboa Francisco Gentil, EPE, Rua Prof. Lima Basto 1099-023 Lisboa, Portugal.
Fátima VazInstituto Português de Oncologia de Lisboa Francisco Gentil, EPE, Rua Prof. Lima Basto 1099-023 Lisboa, Portugal.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Access to genetic testing and counselling in remote areas such as the Madeira archipelago, in the Northern Atlantic Ocean, may be complex. Different counselling methods, including telegenetics, should be explored. In this study, we characterise the Hereditary Breast/Ovarian Cancer (HBOC) families with Madeira ancestry enrolled in our programme. Of a total of 3,566 index patients tested between January 2000 and June 2018, 68 had Madeira ancestry and 22 were diagnosed with a pathogenic germline variant (PV). As in the whole group, BRCA2 PV were more frequent in Madeira patients (68.4%: c.9382C>T (26.3%), c.658_659del (21%), c.156_157insAlu (10.5%), c.793+1G>A (5.3%) and c.298A>T (5.3%). However, the most frequently diagnosed PV in Madeira patients was the BRCA1 c.3331_3334del (31.6%).

Indexed as

founder effectgenetic testinghereditary breast and ovarian cancer syndromepathogenic variant

Identifiers

PMID34567246
PMCPMC8426025

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.